Sugi Predict

Sugi Predict / Compounds / SCHEMBL1765225

SCHEMBL1765225

SCHEMBL1765225

Cc1cc(O)cc(C)c1-c1ccc(C(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.52
▸ TYR P14679 1/20 0.52
▸ GABRA1 P14867 1/20 0.46
▸ GABRB2 P47870 1/20 0.46
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ AKR1C2 P52895 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41
▸ KIF11 P52732 3/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ OPRD1 P41143 1/20 0.40
▸ ESRRB O95718 1/20 0.39
▸ ESRRG P62508 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28225673 0.86 LMNA (0.54) LMNATYRGABRA1GABRB2TSHR
SCHEMBL5953676 0.83 TSHR (0.52) LMNATYRTSHRALDH1A1HPGD
SCHEMBL1765105 0.82 KIF11 (0.55) KIF11MAPT
SCHEMBL6246454 0.81 SENP1 (0.56) ALOX15ESR1KMT2AMEN1GAA
SCHEMBL2652273 0.80 TSHR (0.43) LMNATYRTSHRALDH1A1HPGD
Water SCHEMBL11499545 0.79 SENP1 (0.54) ALOX15ESR1KMT2AMEN1GAA
SCHEMBL8617662 0.78 ESR1 (0.54) LMNATYRTSHRALDH1A1HPGD
SCHEMBL2653612 0.77 ESR2 (0.61) LMNATYRTSHRAKR1C2ESR1
SCHEMBL12620498 0.77 LMNA (0.58) LMNATYRGABRA1GABRB2TSHR
SCHEMBL5608923 0.77 TSHR (0.48) LMNATYRGABRA1GABRB2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108727157-B Process for preparing glucagon receptor antagonist intermediates 大连理工大学 2020-04-28 — — CN claimed
CN-108727157-A The preparation method of glucagon receptor antagonist intermediate 大连理工大学 2018-11-02 — — CN claimed
CN-108727157-B Process for preparing glucagon receptor antagonist intermediates 大连理工大学 2020-04-28 — — CN disclosed
CN-108727157-A The preparation method of glucagon receptor antagonist intermediate 大连理工大学 2018-11-02 — — CN disclosed
US-9550797-B2 Preparation of Grignard reagents using a fluidized bed PATHEON HOLDINGS I B.V. (NL) 2017-01-24 — — US disclosed
US-9550797-B2 Preparation of Grignard reagents using a fluidized bed PATHEON HOLDINGS I B.V. (NL) 2017-01-24 — — US disclosed
US-20160137669-A1 PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED PATHEON HOLDINGS I B.V. (NL) 2016-05-19 — — US disclosed
US-20160137669-A1 PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED PATHEON HOLDINGS I B.V. (NL) 2016-05-19 — — US disclosed
WO-2014207206-A1 PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED DPX HOLDINGS B.V. (NL) 2014-12-31 — — WO disclosed
EP-1957068-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2014-08-13 — — EP disclosed
US-8609892-B2 Glucagon receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2013-12-17 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
WO-2007114855-A2 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-10-11 — — WO disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 — — EP disclosed
WO-2006086488-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-08-17 — — WO disclosed
WO-2006086488-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-08-17 — — WO disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137669-A1 PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED GRM4, GRIA4, GRM2 LMNA 3980/4885TYR 2620/4885GABRA1 2555/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR LMNA 3687/4885TYR 1281/4885GABRA1 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.